Due to the coronavirus problem and potentially overloaded hospitals, it may be difficult or undesirable for a patient participating in a clinical trial to obtain their investigational medicinal product (IMP) at the hospital. The FAMHP provides guidelines on this subject.
News FAMHP
There are 14 result(s) found based on your search criteria
11-14 from 14 result(s)
COVID-19: electronic files submission
Following the recommendations of the Belgian National Security Council regarding the coronavirus epidemic, the FAMHP encourages employees to work more from home. Therefore, we ask all our partners to submit their files to us electronically as much as possible.
Give us your opinion on genetically modified vaccines against HPV infections (Human Papilloma Virus)
The FPS Public Health and the FAMHP invite you to take part in the public inquiry on a clinical trial with genetically modified vaccines ChAdOx1-HPV and MVA-HPV against HPV infections (Human Papilloma Virus). The public inquiry runs from March 4, 2020 through April 3, 2020.
Pilot project on simultaneous national scientific advice starts 1 February 2020
The EU-Innovation Network announces a pilot project for simultaneous national scientific advice (SNSA) to strengthen early regulatory support for innovation. The pilot project kicks off with developing a best practice model starting 1 February 2020.